Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenocutuzumab combinations in metastatic breast cancer
NCT03321981Phase 2Completed
- Sponsor
- Merus
- Start
- Jan 2018
- Primary completion
- Oct 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of zenocutuzumab in breast cancer, sponsored by Merus. Started Jan 2018; status: completed.
02
Drugs
zenocutuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03321981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03321981.